rethinkTHC Search
Menu
Study breakdown

Cannabinoids and Cancer: A New Focus on Anti-Inflammatory Effects Beyond Direct Tumor Killing

ReviewModerate evidence
The takeaway

A review highlighted an emerging role for cannabinoids in cancer treatment through anti-inflammatory mechanisms, noting that chronic inflammation promotes cancer and cannabinoids may impact this relationship.

Read this if you are interested in the evolving understanding of how cannabinoids might fight cancer.

Anti-inflammatory effects represent an emerging anti-cancer mechanism beyond direct tumor killing

What the researchers found

While previous cannabinoid-cancer research focused primarily on direct anti-tumor effects (inducing cancer cell death through disrupting signaling pathways like ERK and PI3-K), this review highlighted a newer perspective: cannabinoids as anti-inflammatory agents in cancer.

Chronic inflammation has long been associated with cancer development and progression. The review argued that reducing inflammation could be a mechanism through which cannabinoids impact cancer, distinct from direct cell-killing effects.

The review also noted established clinical uses of cannabinoids in cancer care as anti-emetics and appetite stimulants for cachexia.

The anti-inflammatory approach was described as emerging, with the relationship between chronic inflammation and cancer providing a new therapeutic rationale for cannabinoid use in oncology.

Why it matters

Recognizing anti-inflammatory effects as a separate mechanism for cannabinoid anti-cancer activity opens new therapeutic avenues and could explain benefits that direct tumor-killing mechanisms alone cannot account for.

The numbers in context

Key signaling pathways disrupted by cannabinoids: ERK, PI3-K. Established clinical uses: anti-emetic, appetite stimulation. Emerging application: anti-inflammatory role in cancer.

How the study worked

Narrative review examining the evolving relationship between cannabinoids and cancer, with particular focus on anti-inflammatory mechanisms alongside established pro-apoptotic and anti-proliferative effects.

What this study cannot tell us

The anti-inflammatory anti-cancer mechanism was described as emerging, with limited direct clinical evidence. Anti-inflammatory effects observed in preclinical settings may not translate to clinical cancer outcomes. Immunosuppressive effects could theoretically promote some cancers.

How to read the evidence

Narrative review describing an emerging research direction. Mostly preclinical evidence with a theoretical framework for anti-inflammatory anti-cancer effects.

When this study was published

Published in 2010. The anti-inflammatory role of cannabinoids in cancer has continued to be investigated, with growing preclinical support but limited clinical validation.

The bigger picture

The inflammation-cancer connection is well-established (e.g., aspirin reduces colorectal cancer risk). If cannabinoids reduce cancer-promoting inflammation, they could complement existing anti-inflammatory cancer prevention strategies.

Questions still open

  • Can anti-inflammatory cannabinoid effects be demonstrated in human cancer clinical trials? Which cancers driven by chronic inflammation would be most responsive? How do anti-inflammatory and immunosuppressive effects interact in cancer?

Common questions

Can cannabinoids treat cancer through reducing inflammation?
This is an emerging hypothesis with preclinical support. Chronic inflammation promotes cancer development, and cannabinoids have anti-inflammatory properties. Whether this translates to actual cancer prevention or treatment in humans has not been definitively demonstrated.
Is this different from cannabinoids directly killing cancer cells?
Yes. Previous research focused on cannabinoids inducing cancer cell death or blocking cell growth. The anti-inflammatory mechanism works differently, by reducing the inflammatory environment that promotes cancer development and progression.

Read the original research

Cannabis-derived substances in cancer therapy--an emerging anti-inflammatory role for the cannabinoids.

Current clinical pharmacology, 5(4), 281-7

Citation

Liu, Wai M; Fowler, Daniel W; Dalgleish, Angus G. (2010). Cannabis-derived substances in cancer therapy--an emerging anti-inflammatory role for the cannabinoids.. Current clinical pharmacology, 5(4), 281-7.

Explore the wider topic